Literature DB >> 17513574

Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.

George D Kalliolias, Panagiotis E Georgiou, Ioannis A Antonopoulos, Andrew P Andonopoulos, Stamatis-Nick C Liossis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17513574      PMCID： PMC1954650          DOI： 10.1136/ard.2006.066381

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

2.  Refractory adult onset Still's disease successfully treated with anakinra.

Authors:  F M Vasques Godinho; M J Parreira Santos; J Canas da Silva
Journal:  Ann Rheum Dis       Date:  2004-09-16       Impact factor: 19.103

3.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

4.  Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?

Authors:  E H J G Aarntzen; P L C M van Riel; P Barrera
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

5.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease.

Authors:  Avril A Fitzgerald; Sharon A Leclercq; Alexander Yan; Joanne E Homik; Charles A Dinarello
Journal:  Arthritis Rheum       Date:  2005-06

Review 6.  Adult Still's disease: review of 228 cases from the literature.

Authors:  A Ohta; M Yamaguchi; H Kaneoka; T Nagayoshi; M Hiida
Journal:  J Rheumatol       Date:  1987-12       Impact factor: 4.666

Review 7.  Blocking IL-1 in systemic inflammation.

Authors:  Charles A Dinarello
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307
  7 in total
  32 in total

1.  A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?

Authors:  Francesca Dall'Ara; Micol Frassi; Angela Tincani; Paolo Airò
Journal:  Clin Rheumatol       Date:  2016-01-12       Impact factor: 2.980

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

3.  [Adult onset Still's disease].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 4.  Autoinflammation: translating mechanism to therapy.

Authors:  Taylor A Doherty; Susannah D Brydges; Hal M Hoffman
Journal:  J Leukoc Biol       Date:  2011-02-17       Impact factor: 4.962

Review 5.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

6.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 7.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

8.  Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab.

Authors:  Kazuko Matsumoto; Takao Nagashima; Shino Takatori; Yuta Kawahara; Masaki Yagi; Masahiro Iwamoto; Hitoaki Okazaki; Seiji Minota
Journal:  Clin Rheumatol       Date:  2009-01-30       Impact factor: 2.980

Review 9.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.